Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Evolution For Prestige Brands Combines Near- And Long-Term Strategies

Executive Summary

BC, Goody's, Monistat marketer boosts domestic and international OTC revenues immediately with C.B. Fleet acquisition, looks ahead to manufacturing expansion.

You may also be interested in...



GSK And Reckitt Opting Out Of Pfizer's Consumer Business Sale Speaks Volumes

Reckitt and GSK withdraw from negotiating on potential deals for with Pfizer's consumer business, leaving slim chances Pfizer will receive an acceptable offer from other drug firms mentioned as potential suitors for the business, which it has valued at around $20bn. A spin-off could move to the fore.

GSK And Reckitt Opting Out Of Pfizer's Consumer Business Sale Speaks Volumes

Reckitt and GSK withdraw from negotiating on potential deals for with Pfizer's consumer business, leaving slim chances Pfizer will receive an acceptable offer from other drug firms mentioned as potential suitors for the business, which it has valued at around $20bn. A spin-off could move to the fore.

Prestige Brands' Costs Grow With OTC Portfolio, But Retailer Orders Slow

Consumer products firm's execs also expect "destocking" by drug, grocery and mass merchandise chains and other retail businesses to give way to increased purchase orders, but analysts say losing market share to e-commerce and higher freight costs could be here to stay.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel